Mitigating GLP-1 Related Dermatologic Adverse Effects Through Methylene Blue's Antioxidant Action

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), used for type 2 diabetes and obesity, can cause dermatological side effects such as "Ozempic face," skin laxity, and hair loss due to rapid weight loss. These effects are linked to decreased collagen, elastin, and hydration, as well as oxidative stress and mitochondrial dysfunction. Methylene blue (MB), an antioxidant, may counteract these effects by enhancing mitochondrial function, reducing oxidative stress, and promoting collagen and hair follicle health. When combined with ceramides, MB can help restore skin and hair integrity in patients on GLP-1 therapy, offering a dual-target strategy to mitigate these adverse effects.